OnCo · weekly issue

OnCo weekly, 2026-09-17

147 changelog entries, 1 upcoming date, 14 publications, 91 corrections. Generated from the corpus; every item links to its page and, through it, to the primary source. Not medical advice.

What changed this week

New pages, new data and fixes, from the changelog.

17 September 2026: Papers for 36 more researchers matched by institution; trial snapshots refreshed for all 1,024 products with 136 registry changes detected; paper snapshots refreshed for all 1,924 records
17 September 2026: Navigation starts at the top of the page (scroll attribute on the html tag); footer credit Made with heart and soul by Jude Gomila with Mount Tamalpais and Golden Gate icons in nine languages; roadmap rows 130 to 137
17 September 2026: Every list row has a visual or a designed stand-in (ideas borrow their cancer icon, technology drawing or molecule), with a test so it cannot regress; I-SPY 1, I-SPY 2, I-SPY 2.2, WISDOM and Quantum Leap Healthcare Collaborative linked to Laura Esserman and UCSF; navigation starts at the top of the page; Enter in search opens the results page; roadmap rows 122 to 129
17 September 2026: One papers block per person after the two paper waves met
17 September 2026: People papers: 36 more research-trained people via OpenAlex and Europe PMC
17 September 2026: Company content and sources for 33 makers, 26 sponsor corrections and papers for twelve researchers; 7,065 reverse links take orphaned trials from 2,467 to 279; Wikipedia links for six terms; structured outcomes with sources for 26 trials; 153 new logos; the schematic gauge counts aliased drawings
17 September 2026: Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge
17 September 2026: Schematic gauge counts aliased drawings as specific
17 September 2026: Add Wikipedia links to six terms lacking one
17 September 2026: Fold a doubled relation line after the sponsor merge
17 September 2026: Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them back; orphan floor 2572 to 384
17 September 2026: Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people
17 September 2026: 661 plain-English sentences: every cancer, 201 drugs, 179 technologies, 120 terms, 50 phase 3 trials and 63 targets; 451 reverse links give 126 orphaned drugs and 105 companies their first inbound link, with three maker corrections
17 September 2026: Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list them back; orphan floor 2827 to 2572
17 September 2026: Simple layer: part-o with 661 sentences, layer test
17 September 2026: Machine translation pipeline for record summaries with hash-checked cache and a report link; 157 Chinese summaries live (every cancer page and nine glossary terms) and two Spanish; model review panel populated for twenty cancers by Fable, each verdict tied to the record's own sources
17 September 2026: Every record has its own RDF Turtle file at /api/v1/rdf/<id>.ttl, linked from the page head, the hidden machine links, JSON-LD, the OpenAPI document and llms.txt
17 September 2026: Machine-translated summaries: cached per record and language under public/i18n/summaries, shown only while the English hash matches, marked as machine translated with a report link and an English toggle; prioritised batch script with a fetch call to the Messages API and a validator for NCT ids, doses, gene symbols and leftover English; hand-written Spanish and Chinese examples for pCR; coverage script counts them
17 September 2026: Per-record RDF: one Turtle file per record at /api/v1/rdf/<id>.ttl, linked from every record page
17 September 2026: For me from a real situation: setting, biomarkers, treatments had, country and trial interest drive what is standard, what your biomarkers change, trials that fit, warnings and questions, all from record fields with sources; dependency map renders identically on server and client
17 September 2026: Theme stays light even when React recovers from a hydration mismatch; the counts grid fills its rows again with twenty kinds
17 September 2026: Fix hydration mismatch on the dependency map
17 September 2026: For me from a real situation (roadmap item 101): setting, biomarkers, treatments had, country and trials drive record-backed sections
17 September 2026: Machines of oncology, second wave: 23 more machine families from boron neutron capture and FLASH beams to hyperthermia, fluorescence surgery, positioning, gating and dosimetry, with 32 vendors; roadmap rows marked done for the day's work
17 September 2026: Decisions you may face: a page per cancer laying out each treatment setting's options, evidence and trade-offs; expert centres as a sortable table of what can be measured, with a near-you marker; your remembered cancer follows you through the header, home, hubs, trials and search; a what-changed page per cancer; red cards for warnings on cancer pages
17 September 2026: Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, endoscopy, skin and cervical imaging, RT guidance and QA, CSTDs
17 September 2026: Prostate cancer by state: eight subtype pages from low risk to neuroendocrine, linked from 45 trials and drugs; Tregzi added from the FDA notice and the remaining update bot proposals checked against the registry; Hansoh merged into one record with a redirect
17 September 2026: Patient roadmap 102, 104, 106: remembered cancer, per-cancer what changed, red cards
17 September 2026: Decision pages per cancer and outcome-based centre tables (roadmap items 107 and 108)
17 September 2026: Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge
17 September 2026: Chinese quality pass: 82 TL;DRs corrected (standard NMPA drug names, basket trial term, methotrexate spelling, idioms), account strings in the formal register
17 September 2026: Chinese quality pass on today's TL;DRs and interface strings: 篮式试验 for basket trial, 甲氨蝶呤 typo, 磁共振直线加速器, established drug names in 61 templated trial lines, natural wording in 30 machine-flavoured sentences, 您 throughout the account strings
17 September 2026: First sixty days after diagnosis: a week-by-week guide for every cancer built from its records, and a printable appointment sheet per cancer with questions, words you may hear and treatments you may be offered
17 September 2026: Model review panel: schema, batch script and page for AI model commentary on records, with two example panels; diagnostics wave two: 24 tests from RAD51 foci and CTC counts to pharmacogenomics, cardiac markers and low-resource screening, with five companies; institution networks: Parker Institute members and leaders, CRUK, NCI, UNICANCER and DKTK links, and ten weakly linked centres strengthened
17 September 2026: Add the first 60 days guide and per-cancer appointment sheets
17 September 2026: Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institution pages
17 September 2026: Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)
17 September 2026: Animations pause off screen, when the tab is hidden and on slow phones, with a shared budget of six spinning molecules or drawings at once; the record page sidebar stays inside its column and never reaches the footer
17 September 2026: Model panel: AI models comment on records beside the human review path
17 September 2026: Search results page as an index: kind chips, did-you-mean, pages strip, Ask OnCo card, related strip; 29 trial design terms and a design picker page; startup requests ranked by urgency and commerciality with every input cited; 51 law and regulation terms by jurisdiction with a law page; translation hygiene: language tags, no-translate on names and doses, a browser translation offer
17 September 2026: Animation budget for slower phones: one hook (use-animation-budget) pauses molecules, wireframe schematics, the docking scene, the garden sway, the body map, the resistance map and the steppers when off screen or the tab is hidden, draws a still frame under reduced motion, caps thumbnails at six spinning per kind, animates on tap on Save-Data or four-core devices, defers structure fetches until on screen, lazy-loads the gallery 3D viewer; record page sidebar confined to its grid column and not sticky when taller than the viewport; roadmap rows 127 and 138
17 September 2026: Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)
17 September 2026: Manufacturing in oncology: seven supply chains, 18 technologies and 14 makers; theories of cancer: a hub map and sixteen theory records with status; platform trials at depth: 21 master protocol trials and a hub term; technology dependency map with 119 edges and a viewer; Chinese TL;DRs folded in for every new record
17 September 2026: Browser translation and language attributes (roadmap row 128, part three): summaries, field values, data tables, bullets and table bodies carry lang="en" while TL;DRs keep their own language; drug, gene, company, trial and person names, aka lines, NCT ids, gene symbols, database ids, molecule labels, formulas and doses carry translate="no" with the notranslate class; TranslateOffer shows one dismissible line at the top of the main column that switches to a carried language or explains the browser's translator in nine languages; wireframe canvas labels repeated as hidden real text; scripts/translation-coverage.ts measures the share of a page in the chosen language per kind
17 September 2026: Rank startup requests by urgency and commerciality (row 112)
17 September 2026: Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)
17 September 2026: Search results page as a proper index (roadmap row 123)
17 September 2026: Manufacturing wave: remove the Hitachi remnant
17 September 2026: Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella trials, STAMPEDE enriched
17 September 2026: Theories of cancer: hub map and sixteen theory records in the mechanics section
17 September 2026: One Hitachi record (machines wave)
17 September 2026: Machines of oncology: 21 machine technologies, 17 vendors and 66 centres with their proton, carbon, MR-linac, Gamma Knife and other rare machines, with a machines page; Free in oncology page with 62 services; tumour sequencing tests compared across 13 laboratories; useful 404 page with nearest matches; section tabs, aligned header icons and unsqueezed tables; machine-readable links, Wikidata sameAs and short titles for search engines and agents; footer credit; navigation starts at the top
17 September 2026: Technology dependency DAG viewer (roadmap 134)
17 September 2026: Manufacturing wave: seven supply chains, 18 technologies, 14 makers
17 September 2026: Merge fixes: single Strata Oncology record, Chinese dictionary without duplicate keys
17 September 2026: Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres
17 September 2026: Free in oncology and tumour sequencing test pages (roadmap 117, 118)
17 September 2026: SEO and agent surface on record pages: titles within 60 chars, Wikidata sameAs, hidden machine-readable landmark
17 September 2026: Compact section tabs, table column widths and header icon alignment
17 September 2026: Make the 404 page useful: nearest matches, ways in, local miss log
17 September 2026: Tables: one shared stand-in for rows with no picture, so no visual slot is ever an empty gap
17 September 2026: Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall through to the profile link; drawer close button without a border; pills never break inside a word; page titles capitalised; landing cards show a corner arrow; off-site links open in a new tab; intoDNA STRIDE and Strata Oncology with sequencing links for testing companies; roadmap rows 115 to 121
17 September 2026: Accounts through WorkOS: browser-only sign-in behind the same account functions, recorded in WorkOS, on when the client id is set; README retitled Total information dominance on cancer with an open-repository note and a screenshot gallery; site title to match; pivot modality headers use one classifier so every header links
17 September 2026: Search index is fresh on every visit (service worker network-first for the API, cache rule narrowed to snapshots and images); site pages ranked higher in search; models table shows each maker's logo or an initials tile; orphan detector script and ratchet test; hub page linked from digital twins
17 September 2026: Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancreatic cancer wave: four failed phase 3 programmes, nimotuzumab's NOTABLE approval, elraglusib, their sponsors and cross-links; PDAC and Cloudflare rows on the roadmap
17 September 2026: Merge PRs 25, 28 and 29 (CheckMate split, topic cards, WebMCP); mobile region menu stays on screen; one heading per cancer group; bevacizumab NICE note; glioblastoma MGMT and tovorafenib wording; mathematical models hub and site pages in search; long lists load in pages as you scroll
17 September 2026: Add progressive WebMCP tools for public oncology search and lookup
17 September 2026: fix: filter cancer topic cards by relevance
17 September 2026: fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6
17 September 2026: Pivot headers all link to pages: modality, front, status and phase; new small molecule and cancer vaccine pages; day-long cache headers for snapshots; Cloudflare caching on the roadmap
17 September 2026: Changelog sync keeps the pending entry through the build
17 September 2026: Changelog kept current from the commit log; linked from the README
17 September 2026: Link 51 new technologies back from their drugs, targets and base drawings
17 September 2026: Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers
17 September 2026: Link 28 cancer subtype pages from the drugs and trials that treat them
17 September 2026: Refresh provenance for this week's records
17 September 2026: Cancer links for 20 unlinked trials; Chinese version complete for trials
17 September 2026: Watch button confirms each click
17 September 2026: Country pages: cancer site labels link to their OnCo pages in both tables
17 September 2026: Chinese TL;DRs for the last 87 curated trials and drugs
17 September 2026: Mathematical and biophysical models: 22 model technologies, a third type on the models page
17 September 2026: Types strip as pills, navigator visuals, account-style signup, linked grid headers
17 September 2026: chore: refresh pulse, abstract and citation snapshots (#20)
17 September 2026: chore: refresh institution research output from OpenAlex (#17)
17 September 2026: chore: draft change proposals from feed snapshots
16 September 2026: Add Anocca; biophysics sources as data-source candidates
16 September 2026: Prevalence rows for 20 more targets
16 September 2026: Prevalence rows for 36 targets
16 September 2026: Molecules for 26 more drugs and tracers
16 September 2026: Molecules for 29 more small-molecule drugs
16 September 2026: Pipelines and missing rows for 29 new cancer pages
16 September 2026: Keep the corpus out of the tool pages' JavaScript
16 September 2026: Keep the corpus out of the guideline pages' JavaScript
16 September 2026: Load translation tables on demand; Chinese TL;DRs for 2,678 registry records
16 September 2026: Chinese TL;DRs for the remaining 131 people
16 September 2026: Subtype pages: leiomyosarcoma, liposarcoma, synovial sarcoma, marginal zone lymphoma, cutaneous T-cell lymphoma
16 September 2026: Subtype pages: kidney, testicular, oesophageal, bladder
16 September 2026: Subtype pages: thyroid, head and neck, ovarian
16 September 2026: Chinese TL;DRs for every company, institution, term and idea
16 September 2026: Radiation wave 4 (21 landmark trials) and Chinese TL;DRs for every cancer, target, technology and curated drug
16 September 2026: Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs
16 September 2026: check-links: separate blocked from broken in the report (#15)
16 September 2026: Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112
16 September 2026: Mobile search opens into the box; radiation wave 1
16 September 2026: Add SciRouter, a prevention-first longevity start-up
16 September 2026: Molecules for 31 small-molecule drugs; gumarontinib folded into glumetinib
16 September 2026: Essential thrombocythaemia page, aspirin record, vorolanib
16 September 2026: Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas
16 September 2026: China deep dive: fifteen trial sponsors as company records
16 September 2026: Offline page only on real failures, China wave 1, favicon set
16 September 2026: Registry trials wave 6 and products wave 7
16 September 2026: Clickable breadcrumbs, pipeline products wave 6, checklist additions
16 September 2026: Header signup, trial wave 5 and Ask weighting
16 September 2026: trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recorded drug and cancer (295 to their sponsor); wave 3 trials gain sponsor links; search lifts the kind named at the start of a question so a 'drug for' query ranks drugs above trials and people
16 September 2026: data: pipeline wave 2 from ClinicalTrials.gov, curated: 27 products missing from the corpus (ten China-approved kinase and checkpoint drugs, Japan's amrubicin and pirarubicin, tabelecleucel, HER2 and GDF-15 antibodies, PSMA and CAIX PET tracers, CD45 radioimmunotherapy and others) with 32 phase 3 trial records and China regional rows; launch checklist gains the agentic and AI accessibility to-do
16 September 2026: cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer, NUT carcinoma) with state of the art, history and development pipelines; six trials (TIGER, SABR-COMET, the tazemetostat run-in, three NUT carcinoma trials) and the BET inhibitor ZEN-3694; gaps page counts only developers as missing products
16 September 2026: site: Google Analytics tag with an honest disclosure on the about page; refresh workflows merge their own pull requests once validate and tests pass (the proposals workflow stays a human gate); deploys the FCCT directory and the nine merged weekly snapshots
16 September 2026: chore: draft change proposals from feed snapshots (#1)
16 September 2026: chore: refresh pulse, abstract and citation snapshots (#2)
16 September 2026: chore: refresh trial counts from ClinicalTrials.gov (#3)
16 September 2026: chore: refresh public/votes.json from Discussions reactions (#5)
16 September 2026: chore: weekly citation link check (#7)
16 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#8)
16 September 2026: chore: refresh preprint tracker from Europe PMC (#9)
16 September 2026: chore: check regional approvals against the EMA register (#10)
16 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#11)
16 September 2026: data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and the FCCT directory brought in: 39 suppliers, tools and services and 10 clinics and centres for tissue preservation, tumour profiling, functional drug testing, liquid biopsy, theranostics, vaccines, cell therapy, trial finding and navigation
16 September 2026: owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton therapy trial and an idea on why ADCs have failed in mesothelioma; cancer pages replace the curated Pipeline list with an In development tab built from the whole corpus; Even One Ventures and fourteen portfolio companies with a weekly-refreshed universe list
16 September 2026: data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indication (historic hormonal and cytotoxic agents, photodynamic and diagnostic agents, growth factors, antiemetics, drugs approved in Japan, China, India or Australia); approval pill no longer wraps
16 September 2026: header: profile icon on every page opens an email capture dialog (magic-link sign-in when accounts are on, list endpoint otherwise); weekly-issue signup boxes removed from footer and newsletter page; strings in nine languages

What changed in release 1.0.0 (2026-09-16)

New pages, new data and fixes, from the changelog.

Added: Glossary: twenty canonical categories (mapped at load from the labels written across the data files), one regular category grid with an animation for every category, and a specific picture on every term that has one (its target's schematic, its molecule, its technology's schematic or the organ it concerns) in the table and at the top of the term page.
Added: Email signup: a SignupBox in the footer and on /newsletter/, driven by NEXT_PUBLIC_SIGNUP_ACTION (Buttondown or Listmonk form endpoint); until it is set the box offers the Atom feed and the per-page Watch button.
Added: Initials placeholder (RowAvatar) for startups, organisations and people without a usable logo or portrait; hotlinked favicons that fail or come back as the generic 16 px globe fall back to it.
Added: Journal wordmarks for Nature, the New England Journal of Medicine, Science and The Lancet from Wikidata via their Wikipedia titles, shown on the journals index and journal pages.
Added: Seventeen ChEMBL drug targets (SRC-family kinases, GM-CSF and IL-11 receptors, xanthine oxidase, DNA polymerase alpha, steroid, serotonin, dopamine, opioid and cannabinoid targets) with HGNC, UniProt and ChEMBL links.
Added: Six NCI-listed supportive-care drugs (eltrombopag, romiplostim, emapalumab, fostamatinib, ravulizumab, propranolol as Hemangeol) from FDA labels; the chlorambucil-prednisone regimen from the ECOG trial; six earlier Cancer Statistics reports as key papers.
Added: Papers for sixty-one leaders and OECI representatives via Europe PMC author and affiliation matching, each set checked against the person's role.
Changed: Provenance tags (gap-fill, chembl-gap, ctgov-ingest, nci-list and similar) are hidden from reader-facing pills and excluded from similarity scoring; they remain in the JSON API.
Changed: People pages show one plain-English provenance line under the papers table instead of a fetcher note on every row.
Changed: Table cells wrap long tokens site-wide; the models table's paper column uses short labels with the identifier as hover text.
Changed: Nine dead organisation websites replaced with verified current addresses; four Wikipedia links repointed to existing articles; every Wikipedia and organisation link in the corpus checked.
Changed: NCI drug list credits two-letter regimen acronyms; the completeness matcher no longer drops "AC".
Also in 1.0.0: work unreleased since 0.4.0: Molecule3D: ball-and-stick models of small molecules (CPK colours, shaded spheres, depth-sorted bond cylinders with double and triple bonds, drag to rotate, element legend) and smooth backbone ribbons for proteins (Catmull-Rom through the C-alpha trace, per-chain colours, wider on helices and strands, bound drug in ball-and-stick), with a wireframe toggle. Used on product pages, in every molecule thumbnail, and in a new "Solved structures with a drug bound" panel on target pages.
Also in 1.0.0: work unreleased since 0.4.0: PDB snapshots now keep secondary structure from the HELIX and SHEET records (ss); npm run fetch:structures -- --refresh-pdb 5A9U,5DK3 refreshes chosen entries without touching the rest.
Also in 1.0.0: work unreleased since 0.4.0: Startups and investors: company records gain optional stage, ycBatch, investors, funding (sourced rounds, amounts only where the source states them) and acquiredBy; companyType: "investor" for venture funds, corporate venture arms, an accelerator and disease foundations, whose portfolios are derived from backlinks.
Also in 1.0.0: work unreleased since 0.4.0: 62 Y Combinator companies attacking cancer, drawn from the open YC directory dataset and checked one by one (src/data/companies-yc.ts, snapshot with every hit and its decision in src/data/universe-lists/yc-oncology.json); 187 further venture-backed oncology companies across therapeutics, diagnostics, AI, digital care, radiotherapy hardware, surgery and tools (src/data/companies-startups.ts); 69 investors (src/data/investors.ts).
Also in 1.0.0: work unreleased since 0.4.0: /startups/ (stage strip, YC batch chips, filters by stage, modality, cancer, batch, investor and country, most active investors, recently funded) and /investors/; Funding panel on company pages, Portfolio panel on investor pages; stage and investor facets on /companies/; Startups and Investors in the Institutions & people group.

Upcoming readouts and decisions, next 30 days

Decisions, advisory committees, expected readouts and congresses from the readout calendar. Expected dates are editorial estimates.

2026-09-23 · FDA advisory committee: Galleri multi-cancer early detection test (PMA) (confirmed) · Galleri, GRAIL, Multi-cancer early detection (MCED), NHS-Galleri, PATHFINDER 2 · source

What the journals said, past 14 days

What the leading journals and regulators published, from the research pulse; every item links to the source.

2026-09-08 · Inhibrx claims first win for the long-sought OX40 target: Responses in head and neck cancer, strongest in HPV-positive tumours, after 15 years of failed OX40 programmes at big pharma. (Head and neck squamous cell carcinoma, Immune checkpoint inhibitors)
2026-09-08 · A breakthrough pancreatic cancer drug won approval. Patients still struggle to access it: Insurance barriers after the daraxonrasib approval. (Daraxonrasib, Pancreatic ductal adenocarcinoma)
2026-09-08 · Metabolic syndrome commonly develops in men on ADT plus ARPI: About 40% within a year, per the reported analysis. (Androgen deprivation & AR pathway inhibitors, Prostate cancer, Cardio-oncology)
2026-09-08 · Azacitidine/venetoclax boosts event-free survival in induction-eligible AML: Coverage of the NEJM head-to-head with intensive chemotherapy. (Azacitidine, Venetoclax, Acute myeloid leukaemia)
2026-09-08 · Alcohol-attributable cancer mortality has doubled in the US since 1990: Prevention story with policy implications. (Chemoprevention & risk-reducing surgery)
2026-09-08 · DeLLphi-305: durvalumab + tarlatamab meets OS in first-line maintenance ES-SCLC: 563 patients; first phase 3 T-cell engager OS win in first-line maintenance small-cell lung cancer; numbers pending a congress. (Tarlatamab, Durvalumab, DeLLphi-305, Small-cell lung cancer)
2026-09-08 · Arlocabtagene autoleucel meets primary endpoint in the QUINTESSENTIAL myeloma trial: The GPRC5D CAR-T advances toward filing. (GPRC5D, CAR-T cell therapy, Multiple myeloma)
2026-09-07 · KEYLYNK-001: pembrolizumab ± olaparib maintenance in BRCA-wild-type ovarian cancer: Vergote et al., 7 September: the immunotherapy plus PARP maintenance question in first line. (Pembrolizumab, Olaparib, Ovarian cancer, PARP inhibitors)
2026-09-07 · Lessons from one of the first randomised trials of AI in medicine: Lång, 7 September: what the MASAI mammography-AI trial taught about running AI trials. (AI in radiology, Mammography & tomosynthesis)
2026-09-07 · Oncology dealmaking is becoming more surgical: Buyers target specific modalities and assets rather than platforms. (Antibody-drug conjugate (ADC), Radioligand therapy (beta emitters))
2026-09-05 · Six first-in-class approvals in August, including Etcamah: Camizestrant counted among August's first-in-class approvals. (Camizestrant)
2026-09-04 · Accelerated approval: camizestrant + CDK4/6 inhibitor for ESR1-mutated HR+/HER2- breast cancer: Etcamah approved 4 September after a 6-3 negative advisory vote, on SERENA-6 ctDNA-guided switching data. (Camizestrant, SERENA-6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer)
2026-09-04 · Etcamah grabs FDA approval for advanced breast cancer with ESR1 mutations: Camizestrant plus a CDK4/6 inhibitor, accelerated approval. (Camizestrant, HR-positive / HER2-negative breast cancer)
2026-09-04 · Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodelling: Stroma as a therapeutic target after chemotherapy. (FAP, Epithelial-mesenchymal transition & drug efflux)

Corrections, past 7 days

Confirmed factual corrections to the corpus, with the fixing commit.

2026-09-17 · checkmate-548: One record named "CheckMate 548 & CheckMate 143 & CheckMate 498" carried a single registry id (NCT02667587, which is CheckMate 548 only) and yearReported 2020 for all three. They are three separate trials: CheckMate 143 (NCT02017717, JAMA Oncology 2020), CheckMate 498 (NCT02617589, Neuro-Oncology 2023) and CheckMate 548 (NCT02667587, Neuro-Oncology 2022). The glioma history also dated CheckMate 143 to 2017 while the record said 2020. (Reader report (neurosurgeon), checked against ClinicalTrials.gov and the PubMed records (143, 498, 548)) · split into checkmate-143, checkmate-498, checkmate-548, each with its own registry id, publication, year and outcomes; history entry moved to 2020
2026-09-17 · checkmate-548: The structured overall-survival outcome (28.9 vs 32.1 months) cited academic.oup.com/neuro-oncology/article/25/1/123, which is the CheckMate 498 paper (Omuro et al.), not CheckMate 548 (Lim et al., Neuro-Oncology 2022;24:1935-1949). (Reader report (neurosurgeon), checked against PubMed (source)) · source set to https://doi.org/10.1093/neuonc/noac116
2026-09-13 · nct05208047: status was "recruiting"; the registry says RECRUITING; primary completion 2025-09-30. (Weekly registry fact check (source)) · set to "active" via apply-factcheck
2026-09-13 · alphabreak: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Weekly registry fact check (source)) · set to "active" via apply-factcheck
2026-09-13 · alphabreak: phase was "3"; the registry says PHASE2. (Weekly registry fact check (source)) · set to "2" via apply-factcheck
2026-09-13 · cambria: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Weekly registry fact check (source)) · set to "active" via apply-factcheck
2026-09-13 · mountaineer: status was "recruiting"; the registry says COMPLETED. (Weekly registry fact check (source)) · set to "completed" via apply-factcheck
2026-09-13 · mountaineer: phase was "3"; the registry says PHASE2. (Weekly registry fact check (source)) · set to "2" via apply-factcheck
2026-09-11 · acupuncture-aromatase-inhibitor-arthralgia, retifanlimab, b-combination-space, basement-membrane-tissue-barriers, kenneth-kinzler, cbt-fatigue-distress, multidisciplinary-tumour-board: Seven cited DOIs did not resolve (mistyped or belonging to another article); the intended papers were re-identified through Crossref with journal and DOI prefix pinned, for example POD1UM-303 to 10.1016/S0140-6736(25)00631-2 and the FAP locus paper to 10.1126/science.1651562. Two more (rEECur, NUT carcinoma registry) could not be identified and were removed; the small bowel adenocarcinoma guideline DOI now points at the ASCO guidelines index. (Link check (doi.org 404)) · URLs corrected
2026-09-11 · 46 records with a Wikipedia link, 13 with a Wikipedia-only source: The Wikipedia article title in wikipedia or links no longer exists (for example Oncotype_DX, PSMA_PET, Immuno-PET). Titles were checked against the Wikipedia API; one was renamed (Biosecure Act), the rest removed. BCLC staging and cardio-oncology now cite their primary guideline papers instead. (Link check (404)) · references removed or replaced
2026-09-11 · 33 dead pages (fda.gov, cancer.gov, institutional and company pages): Pages returned 404 to a browser as well as to the checker; replaced with the nearest Wayback Machine snapshot and labelled "(archived copy)". 45 pages whose publisher moved them now point at the nearest live section of the same site, labelled "(page moved; nearest live section)"; 101 dead links on records that keep another source were removed. accessdata.fda.gov and doi.org answer non-browser clients with 404 or 403, so those were verified with a browser user agent and left as they were. (Link check) · URLs replaced or removed
2026-09-11 · elevate-tn: nct was NCT02475097, which does not exist on ClinicalTrials.gov; the acalabrutinib ELEVATE-TN study is NCT02475681 (acronym ElevateTN). (Registry fact check (nct-not-found), confirmed against the registry entry) · set to NCT02475681
2026-09-11 · ace-breast-02: nct was NCT04829604, which is the separate US phase 2 study ACE-Breast-03 (72 patients); ACE-Breast-02 is registered in China only. (Registry fact check: phase and enrolment disagreed, registry title names ACE-Breast-03) · id removed; the primary publication is the source
2026-09-11 · preopanc: nct was NCT02172976, a 40-patient German gemcitabine versus FOLFIRINOX study, not the Dutch PREOPANC trials. (Registry fact check: enrolment 40 versus 246 and a different title) · set to NTR3709 (Netherlands Trial Register) and cite the JCO 2020 and JCO 2022 papers
2026-09-11 · iberdomide: Status "phase-3" with no US approval; openFDA holds the Zenbexus label, effective 13 August 2026, for relapsed myeloma with daratumumab and dexamethasone. (Registry fact check (openFDA label exists, not recorded as approved)) · status approved, approvals row and DailyMed link added; regional table updated
2026-09-11 · daraxonrasib: regional-approvals.ts still said "under review" while the record and the FDA novel approvals page record approval on 26 August 2026 (Rasonque). (Audit (approvals disagree with the regional table)) · regional row set to approved 2026
2026-09-11 · nintedanib: Status "negative" although the EMA authorised Vargatef for lung adenocarcinoma with docetaxel in 2014; the mesothelioma failure is one programme, not the molecule's status. (Audit (status disagrees with approvals)) · status approved, EMA EPAR linked, TL;DR reworded
2026-09-11 · atrt, chordoma, epithelioid-sarcoma, epigenetics-roadmap: Standard-of-care rows, pipelines and a roadmap step still presented tazemetostat as available; Ipsen withdrew it from all markets in March 2026. (Audit (standard of care and pipeline cite a withdrawn item)) · rows reworded to state the withdrawal, removed from pipelines, roadmap step notes it
2026-09-11 · mds: Pipeline listed magrolimab, stopped in 2024. (Audit (pipeline cites a withdrawn item)) · removed
2026-09-11 · hairy-cell-leukemia: Row said moxetumomab pasudotox "where still available"; it was withdrawn from sale in 2023. (Audit (standard of care cites a withdrawn item)) · reworded
2026-09-11 · docetaxel, durvalumab, ibrutinib, lenalidomide, pegylated-liposomal-doxorubicin, temsirolimus, dabrafenib-trametinib: approvals[] began later than the first approval: docetaxel 1996 (Taxotere, breast), durvalumab 2017 (urothelial, accelerated), ibrutinib US 2013 (MCL) and EU 2014, lenalidomide 2005 (MDS del(5q)), Doxil 1995 (Kaposi sarcoma); temsirolimus EU year was 2009 (Torisel authorised November 2007, MCL added 2009); the dabrafenib plus trametinib combination was approved in the US in January 2014 (regional table said 2013, the single agents). (Audit (approvals disagree with the regional table) and Drugs@FDA earliest original approval) · rows added or corrected
2026-09-11 · lacc: Text quoted a death hazard ratio of 6.00 while the only structured outcome carried the disease-free survival HR 3.74. (Audit (number in the text disagrees with the structured field)) · overall survival outcome added from NEJM 2018
2026-09-11 · peace-1: Result gave only the overall-population OS HR 0.82 while the structured outcome carried the ADT plus docetaxel population HR 0.75. (Audit (number in the text disagrees with the structured field)) · result states both populations
2026-09-11 · bevacizumab, cabozantinib, everolimus, ivosidenib, lenvatinib, letrozole, ramucirumab, regorafenib, sunitinib, trabectedin, Eisai, Exelixis, Incyte: Each was defined in full by two or three cancer deep dives with different summaries, mechanisms and approval rows; only the first copy was ever shown and the rest were silently hidden. (Audit (duplicates with different values)) · second copies became supplements: relationship arrays, extra approval rows and cancer-specific facts as notes
2026-09-11 · alfa-0701: enrolled was "271"; the registry says 280 (ACTUAL). (Registry fact check (source)) · set to "280" via apply-factcheck
2026-09-11 · alter-0303: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · amplify-7p: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · apt-trial: enrolled was "410"; the registry says 406 (ACTUAL). (Registry fact check (source)) · set to "406" via apply-factcheck
2026-09-11 · ascertain-v: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · belinda: enrolled was "322"; the registry says 330 (ACTUAL). (Registry fact check (source)) · set to "330" via apply-factcheck
2026-09-11 · camel: enrolled was "412"; the registry says 419 (ACTUAL). (Registry fact check (source)) · set to "419" via apply-factcheck
2026-09-11 · cartitude-5: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · checkmate-9dw: enrolled was "668"; the registry says 732 (ACTUAL). (Registry fact check (source)) · set to "732" via apply-factcheck
2026-09-11 · checkmate-9er: enrolled was "651"; the registry says 701 (ACTUAL). (Registry fact check (source)) · set to "701" via apply-factcheck
2026-09-11 · cll14: enrolled was "432"; the registry says 445 (ACTUAL). (Registry fact check (source)) · set to "445" via apply-factcheck
2026-09-11 · anbl0532: enrolled was "652"; the registry says 665 (ACTUAL). (Registry fact check (source)) · set to "665" via apply-factcheck
2026-09-11 · compete: enrolled was "309"; the registry says 324 (ACTUAL). (Registry fact check (source)) · set to "324" via apply-factcheck
2026-09-11 · desktop-iii: enrolled was "407"; the registry says 408 (ACTUAL). (Registry fact check (source)) · set to "408" via apply-factcheck
2026-09-11 · destiny-breast12: enrolled was "504"; the registry says 506 (ACTUAL). (Registry fact check (source)) · set to "506" via apply-factcheck
2026-09-11 · dreamseq: enrolled was "265"; the registry says 267 (ACTUAL). (Registry fact check (source)) · set to "267" via apply-factcheck
2026-09-11 · emerald-3: enrolled was "725"; the registry says 760 (ACTUAL). (Registry fact check (source)) · set to "760" via apply-factcheck
2026-09-11 · epcore-nhl-1: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · foenix-cca2: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · golseek-1: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · her2climb-02: enrolled was "463"; the registry says 466 (ACTUAL). (Registry fact check (source)) · set to "466" via apply-factcheck
2026-09-11 · herizon-gea-01: enrolled was "914"; the registry says 920 (ACTUAL). (Registry fact check (source)) · set to "920" via apply-factcheck
2026-09-11 · horizon-breast01: enrolled was "366"; the registry says 381 (ACTUAL). (Registry fact check (source)) · set to "381" via apply-factcheck
2026-09-11 · imroz: enrolled was "446"; the registry says 475 (ACTUAL). (Registry fact check (source)) · set to "475" via apply-factcheck
2026-09-11 · inavo120: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · keynote-483: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · ion-trial: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · izabright-breast01: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · lacc: enrolled was "631"; the registry says 636 (ACTUAL). (Registry fact check (source)) · set to "636" via apply-factcheck
2026-09-11 · legend-2: phase was "1"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · lidera: enrolled was "4200"; the registry says 4170 (ACTUAL). (Registry fact check (source)) · set to "4170" via apply-factcheck
2026-09-11 · litespark-005: enrolled was "746"; the registry says 755 (ACTUAL). (Registry fact check (source)) · set to "755" via apply-factcheck
2026-09-11 · lume-meso: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · maps: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · matterhorn: enrolled was "948"; the registry says 957 (ACTUAL). (Registry fact check (source)) · set to "957" via apply-factcheck
2026-09-11 · mevpro-1: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · orient-32: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · orient-32: enrolled was "571"; the registry says 595 (ACTUAL). (Registry fact check (source)) · set to "595" via apply-factcheck
2026-09-11 · outback: enrolled was "919"; the registry says 926 (ACTUAL). (Registry fact check (source)) · set to "926" via apply-factcheck
2026-09-11 · persevera: enrolled was "978"; the registry says 992 (ACTUAL). (Registry fact check (source)) · set to "992" via apply-factcheck
2026-09-11 · phergain: enrolled was "356"; the registry says 377 (ACTUAL). (Registry fact check (source)) · set to "377" via apply-factcheck
2026-09-11 · quilt-3-032: phase was "2"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · rxponder: enrolled was "5083"; the registry says 5018 (ACTUAL). (Registry fact check (source)) · set to "5018" via apply-factcheck
2026-09-11 · senticol-iii: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · stellar: enrolled was "80"; the registry says 82 (ACTUAL). (Registry fact check (source)) · set to "82" via apply-factcheck
2026-09-11 · viale-a: enrolled was "431"; the registry says 443 (ACTUAL). (Registry fact check (source)) · set to "443" via apply-factcheck
2026-09-11 · waveline-003: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · her2climb: phase was "3"; the registry says PHASE2. (Registry fact check (source)) · set to "2" via apply-factcheck
2026-09-11 · imcgp100-202: phase was "3"; the registry says PHASE2. (Registry fact check (source)) · set to "2" via apply-factcheck
2026-09-11 · ken-she: phase was "3"; the registry says PHASE4. (Registry fact check (source)) · set to "4" via apply-factcheck
2026-09-11 · amplify-7p: enrolled was "144"; the registry says 158 (ACTUAL). (Registry fact check (source)) · set to "158" in trial-outcomes.ts
2026-09-11 · eortc-26981: enrolled was "573"; the registry says 575 (ACTUAL). (Registry fact check (source)) · set to "575" in trial-outcomes.ts
2026-09-11 · keynote-355: enrolled was "847"; the registry says 882 (ACTUAL). (Registry fact check (source)) · set to "882" in trial-outcomes.ts
2026-09-11 · litespark-012: enrolled was "1688"; the registry says 1854 (ACTUAL). (Registry fact check (source)) · set to "1854" in trial-outcomes.ts
2026-09-11 · pathfinder-2: enrolled was "35878"; the registry says 35883 (ACTUAL). (Registry fact check (source)) · set to "35883" in trial-outcomes.ts
2026-09-11 · rasolute-302: enrolled was "460"; the registry says 500 (ACTUAL). (Registry fact check (source)) · set to "500" in trial-outcomes.ts
2026-09-11 · tropion-breast03: enrolled was "1075"; the registry says 1174 (ACTUAL). (Registry fact check (source)) · set to "1174" in trial-outcomes.ts
2026-09-11 · tropion-lung01: enrolled was "604"; the registry says 605 (ACTUAL). (Registry fact check (source)) · set to "605" in trial-outcomes.ts
2026-09-11 · flaura2: enrolled was "557"; the registry says 587 (ACTUAL). (Registry fact check (source)) · set to "587" in trial-outcomes.ts
2026-09-11 · impassion131: enrolled was "651"; the registry says 653 (ACTUAL). (Registry fact check (source)) · set to "653" in trial-outcomes.ts
2026-09-11 · latitude: enrolled was "1199"; the registry says 1209 (ACTUAL). (Registry fact check (source)) · set to "1209" in trial-outcomes.ts
2026-09-11 · olympia: enrolled was "1836"; the registry says 1837 (ACTUAL). (Registry fact check (source)) · set to "1837" in trial-outcomes.ts
2026-09-11 · psmafore: enrolled was "468"; the registry says 469 (ACTUAL). (Registry fact check (source)) · set to "469" in trial-outcomes.ts
2026-09-11 · splash: enrolled was "412"; the registry says 455 (ACTUAL). (Registry fact check (source)) · set to "455" in trial-outcomes.ts
2026-09-11 · therap: enrolled was "200"; the registry says 201 (ACTUAL). (Registry fact check (source)) · set to "201" in trial-outcomes.ts
2026-09-11 · vision: enrolled was "831"; the registry says 861 (ACTUAL). (Registry fact check (source)) · set to "861" in trial-outcomes.ts
2026-09-11 · xalute: enrolled was "675"; the registry says 707 (ACTUAL). (Registry fact check (source)) · set to "707" in trial-outcomes.ts